Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Adrenaline may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for EpiPen® contains a sterile solution of adrenaline for emergency injection into the outer part of the thigh muscle (intramuscular injection). EpiPen® is to be used for the emergency treatment of sudden life-threatening allergic reactions (anaphylactic shock) to insect stings or bites, foods or drugs or exercise. The reaction is the result of the body trying to protect itself from the allergen (the foreign substance that causes the allergy) by releasing chemicals into the blood stream. Sometimes the cause of the allergic reaction is not known. Symptoms that signal the onset of an anaphylactic shock occur within minutes of exposure to the allergen and include: itching of the skin; raised rash (like a nettle rash); flushing; swelling of the lips, throat, tongue, hands and feet; wheezing; hoarseness; shortness of breath; nausea; vomiting; stomach cramps and in some cases, loss of consciousness. The medicine in EpiPen® is adrenaline which is an adrenergic drug. It works directly on the cardiovascular (heart and circulation) system and respiratory (lung) system, to stop the possible fatal effects of anaphylactic shock by very quickly making the blood vessels smaller, relaxing muscles in the lungs to improve breathing, reducing swelling and increase heart rate. The EpiPen® is intended for immediate self-administration by a person with a history or recognised risk of going into anaphylactic shock. If you are at risk, you should always keep your EpiPen® with you. It is designed as an emergency rescue therapy but you must get medical attention as soon as possible after its use.
e EpiPen® Do not use EpiPen® There is no known reason why anyone should not use EpiPen® during an allergic emergency. Take special care with EpiPen® Adrenaline is essential for the treatment of anaphylaxis. However, take special care with EpiPen®:
• • • • •
Medicines for thyroid disease. Medicines that make you breathe more easily; used for asthma (theophylline). Medicines used in labour (oxytocin). Medicines used to treat allergies such as diphenhydramine or chlorpheniramine (antihistamines). Medicines that act on the nervous system (parasympatholytics).
Diabetic patients should carefully monitor their glucose levels after use of EpiPen® as adrenaline can reduce the amount of insulin made by the body, thus increasing the blood glucose level. Pregnancy, breast-feeding and fertility Pregnancy Ask your doctor or pharmacist for advice before taking any medicine. There is limited experience of the use of adrenaline during pregnancy. If you are pregnant, do not hesitate to use EpiPen® in an emergency, since you and your baby's lives may be in danger. Discuss this with your doctor if you are pregnant. Breast-feeding EpiPen® would not be expected to have any effect on the nursing infant. Fertility Adrenaline is a substance that naturally occurs in the body, it is unlikely that EpiPen® would have any detrimental effects on fertility. Driving and using machines The ability to drive and use machines is unlikely to be affected by the administration of an adrenaline injection but may be affected by an anaphylactic reaction. If affected do not drive. EpiPen® contains sodium metabisulphite and sodium chloride EpiPen® contains sodium metabisulphite (E223), which may in rare cases, cause severe allergic reactions (hypersensitivity) or breathing difficulty (bronchospasm). However, you should still use the EpiPen® in line with the advice from your healthcare professional. This medicine contains less than 23 mg sodium per dose, i.e. essentially 'sodium-free'. 3. How to use EpiPen® When your doctor prescribes EpiPen®, you must make sure you understand the reason it has been prescribed for you. You should be confident that you know exactly how and when to use it. Always use EpiPen® exactly as your doctor or pharmacist has told you. If you are at all unsure about
it, ask to have the instructions repeated by your doctor, nurse or pharmacist. It is recommended that your family members, carers or teachers are also instructed in the correct use of EpiPen®. Dosage The usual adult dose for allergic emergencies is 0.3 mg adrenaline for injection into muscle (intramuscular use). EpiPen® is intended to be used by people with a body weight above 25 kg (3 stone 13 lbs). For persons weighing less than 25 kg (3 stone 13lbs) EpiPen® Jr. may be more appropriate for use. If you notice the signs of an acute allergic reaction, use EpiPen® immediately, through your clothing if necessary. Each EpiPen® delivers one single dose of 0.3 ml liquid which is equal to 0.3 mg (300 micrograms) adrenaline. After use a volume of 1.7 ml will remain in the EpiPen® but this cannot be reused.
Sometimes a single dose of adrenaline may not be sufficient to completely reverse the effects of a serious allergic reaction. For this reason, your doctor is likely to prescribe two EpiPen® for you. If your symptoms have not improved or have deteriorated within 5 minutes after the first injection, either you or the person with you should give a second injection. For this reason you should carry two EpiPen® with you at all times. Method of administration The EpiPen® is designed to be used easily by people without medical training. EpiPen® should be jabbed firmly against the outer portion of the thigh from a distance of approximately 10 cm (4 inches). There is no need for precise placement in the outer portion of the thigh. When you jab the EpiPen® firmly into your thigh, a spring activated plunger will be released, which pushes the hidden needle into the thigh muscle and administers a dose of adrenaline. If you are wearing clothes the EpiPen® can be injected through the clothes. The instructions for use of the EpiPen® given below must be carefully followed. EpiPen® should only be injected into the outer thigh. It should not be injected into the buttocks (your bottom). Directions for use Before you ever need to use it, fully familiarise yourself with the EpiPen®, when and how it should be used (refer to diagram 1). Follow these directions only when ready to use. Hold the EpiPen® by the middle, never by the ends. For proper administration, look at the diagrams and follow these steps:
What to do in an emergency:
A small air bubble may be present in EpiPen®. It does not affect the way the product works. Even though most of the liquid (about 90 %) remains in the EpiPen® after use, it cannot be reused. EpiPen® is for single use only. The correct dose has been administered if the orange needle tip is extended and the window is obscured. Always seek medical help immediately after using EpiPen®. Dial 999- say anaphylaxis ("ana-fillaxis") and ask for an ambulance, even if symptoms are improving. You will need to go to the hospital for observation and further treatment as required. This is because the reaction may happen again at some time later. While waiting for the ambulance, ask someone to stay with you until the ambulance arrives in case you feel unwell again. Unconscious patients should be placed on their side in the recovery position. Make sure that you inform the healthcare professional that you have received an intramuscular injection of adrenaline and hand over the EpiPen® to them for safe disposal. If you use more EpiPen® than you should In case of overdose or accidental injection of the adrenaline, you should always seek immediate medical help. Your blood pressure may rise sharply and it will need to be monitored. If you have any further questions on the use of this medicine; ask your doctor, pharmacist or nurse.
Like all medicines this medicine can cause side effects, although not everybody gets them. Seek urgent medical advice immediately in case of accidental injection. Accidental injection of EpiPen® in hands or fingers have been reported and may result in lack of blood supply to these areas. Adverse reactions experienced as a result of accidental injections may include increased heart rate, local reactions including injection site paleness, coldness and numbness or injury at the injection site resulting in bruising, bleeding, discoloration, redness or skeletal injury.
Tell your doctor or pharmacist if any of the following side effects occur or worsen. Rare (may affect up to 1 in 1,000 people) Cardiomyopathy has been seen in patients treated with adrenaline. Not known (frequency cannot be estimated from the available data): Usual side effects include: irregular heartbeat, palpitations, severe rapid heartbeats, severe chest pains, high blood pressure, reduced blood flow to limbs, sweating, nausea, vomiting, difficulty breathing, paleness, headache, dizziness, weakness, tremor and apprehension, nervousness or anxiety, injection site infection, injection site bruising, bleeding, discoloration, redness of the skin and skeletal injury. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
EpiPen® Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label and carton. The expiry date refers to the last day of that month. Do not store above 25 °C. Do not refrigerate or freeze. Keep container in the outer carton in order to protect from light. When exposed to air or light, adrenaline deteriorates rapidly and will become pink or brown. Please remember to check the contents of the glass cartridge in the EpiPen® Auto-injector from time to time to make sure the liquid is still clear and colourless. Do not use this medicine if you notice that the liquid is unclear, coloured or contains solid particles. Replace the EpiPen® Auto-injector by the expiry date or earlier if the solution is discoloured or contains a precipitate (solid particles). Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. See also section 3 – Directions for use.
What EpiPen® contains The active substance is adrenaline 0.3 mg (300 microgram). The other ingredients are: Sodium Chloride, Sodium Metabisulphite (E223), Hydrochloric Acid, Water for Injections. What EpiPen® looks like and contents of the pack Clear and colourless solution in a pre-filled pen (Auto-injector). The Auto-injector (single-dose) contains 2 ml solution for injection. Each auto-injector delivers one single dose (0.3 ml) of adrenaline. The EpiPen® exposed needle length is approximately 15 mm. Pack sizes: 1 x auto-injector. 2 x auto-injectors. Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer Marketing authorisation holder: Viatris Products Limited, Station Close, Potters Bar, EN6 1TL, United Kingdom. Manufacturer: MEDA Pharma GmbH & Co. KG, Benzstrasse 1, 61352 Bad Homburg, Germany This leaflet was last revised in June 2026. If this leaflet is difficult to see or read and you would like it in a different format, please contact Viatris Products Limited, Station Close, Potters Bar, EN6 1TL, United Kingdom.
The active substance in EpiPen Adrenaline (Epinephrine) 0.3 mg Auto-Injector is adrenaline.
This leaflet reproduces the patient information leaflet approved for EpiPen Adrenaline (Epinephrine) 0.3 mg Auto-Injector, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
EpiPen® is an automatic injection device containing adrenaline for allergic emergencies. It should be used only by a person with a history or an acknowledged risk of an anaphylactic reaction. EpiPen® is indicated in the emergency treatment of allergic reactions (anaphylaxis) to insect stings or bites, foods, drugs and other allergens as well as idiopathic or exercise induced anaphylaxis. Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhoea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritis, rashes, urticaria or angioedema.
For these reasons EpiPen® should always be carried by such persons in situations of potential risks.
Adrenaline is considered the first line drug of choice for allergic emergencies. Adrenaline effectively reverses the symptoms of rhinitis, urticaria, bronchospasm and hypotension because it is a pharmacological antagonist to the effects of the chemical mediators on smooth muscles, blood vessels and other tissues. Adrenaline is recommended as the initial and primary therapeutic agent in the treatment of anaphylaxis by every recognised authority in allergy, and its appropriate use in these circumstances is widely documented in the medical literature.
Posology:
EpiPen® is for intramuscular administration.
It is designed for easy use by the lay person and has to be considered as first aid. EpiPen® delivers a single dose 0.3 ml injection equal to 0.3 mg adrenaline when activated.
EpiPen® auto-injector 0.3 mg is recommended for people with a body weight above 25 kg. For persons weighing less than 25 kg, EpiPen® Jr. auto-injector 0.15 mg is recommended.
The usual adrenaline adult dose for allergic emergencies is 0.3 mg. For paediatric use, the appropriate dosage may be 0.15 mg or 0.3 mg depending upon the body weight of the patient (0.01 mg/kg body weight). The prescribing physician has the option of prescribing more or less than these amounts based on careful assessment of each individual patient and recognising the life-threatening nature of reactions for which this is being prescribed. EpiPen® comes in 0.15 mg and 0.3 mg strengths. The physician should consider using other forms of injectable adrenaline if lower doses are felt to be necessary for small children.
An initial dose should be administered as soon as symptoms of anaphylaxis are recognised. In the absence of clinical improvement or if deterioration occurs after the initial treatment, a second injection with an additional EpiPen® may be administered 5 – 15 minutes after the first injection. It is recommended that patients are prescribed two EpiPen® auto-injectors which they should carry at all times.
As EpiPen® is designed as emergency treatment only, the patient should be advised to always seek medical help immediately.
A physician who prescribes EpiPen® should take appropriate steps to ensure that the patient understands the indications and how to use their device. The physician should review with the patient, or any other person who might be in a position to administer EpiPen® to the patient experiencing anaphylaxis, in detail, the patient instructions and how to use EpiPen®.
Method of administration:
Inject the delivered dose of the EpiPen® auto-injector (0.3 ml equal to 0.3 mg) into the anterolateral aspect of the thigh, through clothing if necessary. See detailed instructions for use, section 6.6.
The patient/carer should be informed that following each use of EpiPen®:
• They should call for immediate medical assistance, ask for an ambulance and state 'anaphylaxis' even if symptoms appear to be improving (see section 4.4)
• Conscious patients should preferably lie flat with feet elevated but sit up if they have breathing difficulties. Patients should lie down again as soon as they can and stay lying down even if they are feeling better. Unconscious patients should be placed on their side in the recovery position.
• The patient should if possible remain with another person until medical assistance arrives.
There are no known absolute contraindications to the use of EpiPen® during an allergic emergency. Clinical conditions where special precautions are advised and drug interactions are prescribed in sections 4.4 and 4.5.
All patients who are prescribed EpiPen® should be thoroughly instructed to understand the indications for use and the correct method of administration (see section 6.6). It is strongly advised also to educate the patient's immediate associates (e.g. parents, caregivers, teachers) on the correct use of EpiPen® in case support is needed in the emergency situation.
Adrenaline is ordinarily administered with extreme caution to patients who have a heart disease. Adrenaline should only be prescribed to those patients, and elderly individuals if the potential benefit justifies the potential risk.
There is a risk of adverse reactions following adrenaline administration in patients with severe renal impairment, prostatic adenoma leading to residual urine, hypercalcaemia and hypokalaemia. In patients with Parkinson's disease, adrenaline may be associated with a transient worsening of Parkinson's symptoms such as rigidity and tremor.
Use of adrenaline with drugs that may sensitise the heart to arrhythmias, e.g., digitalis, mercurial diuretics, or quinidine, ordinarily is not recommended. Anginal pain may be induced by adrenaline in patients with coronary insufficiency.
Hyperthyroid individuals (hyperfunction of the thyroid gland), individuals with cardiovascular disease, hypertension (raised blood pressure), or diabetes, elderly individuals, pregnant women, and children under 25 kg body weight using EpiPen® may theoretically be at greater risk of developing adverse reactions after adrenaline administration.
In patients with angle-closure glaucoma, adrenaline induces pupil dilation (mydriasis), which can precipitate an acute angle-closure episode by further narrowing the drainage angle. In contrast, in open-angle glaucoma, adrenaline lowers intraocular pressure by reducing aqueous humor production and enhancing outflow through the trabecular meshwork.
Accidental injection into the hands or feet may result in loss of blood flow to the affected area and should be avoided. If there is an accidental injection into these areas, advise the patient to go immediately to the nearest hospital emergency department for treatment.
The patient should be instructed to check the contents of the glass cartridge in the auto-injector periodically through the viewing window of the unit to make sure the solution is clear and colourless. The auto-injector should be discarded if discoloured or contains a precipitate. For emergency treatment, use of EpiPen® with discoloured contents may be recommended rather than to delay the treatment.
EpiPen® should ONLY be injected into the anterolateral aspect of the thigh. Patients should be advised NOT to inject into the buttock. Large doses or accidental intravenous injection of adrenaline may result in cerebral haemorrhage due to sharp rise in blood pressure. Directions for proper use of the auto-injectors must be followed in order to avoid intravenous injection. Rapidly acting vasodilators can counteract the marked pressor-effects of adrenaline.
In case of injection performed by a caregiver, immobilisation of the patient's leg should be ensured during injection to minimise the risk of injection site laceration.
EpiPen® is for single use only and cannot be reused.
In patients with a thick subcutaneous fat layer, there is risk for adrenaline not reaching the muscle tissue resulting in a suboptimal effect (see section 5.2). A second injection with an additional EpiPen® may be needed (see section 4.2).
The adrenaline solution contains sodium metabisulphite, a sulphite that may in other products cause severe hypersensitivity reactions including anaphylactic symptoms or life-threatening or less severe asthmatic episodes in certain susceptible persons, especially those with a history of asthma. The alternatives to using adrenaline in a life-threatening situation may not be satisfactory. The presence of a sulphite in this product should not deter administration of the drug for treatment of serious allergic or other emergency situations.
Adrenaline is essential for the treatment of anaphylaxis. Therefore, patients with these conditions, and/or any other person who might be in a position to administer EpiPen® to a patient experiencing anaphylaxis should be carefully instructed in regard to the circumstances under which this life-saving medication should be used.
The patient/carer should be informed about the possibility of biphasic anaphylaxis which is characterised by initial resolution followed by recurrence of symptoms some time later.
Patients with concomitant asthma may be at increased risk of severe anaphylactic reaction.
Patients should be warned regarding related allergens and should be investigated whenever possible so that their specific allergens can be characterised.
This medicinal product contains less than 1 mmol (23mg) per dose, i.e. essentially 'sodium-free'.
Caution is indicated in patients receiving drugs that may sensitise the heart to arrhythmias, including digitalis, mercurial diuretics or quinidine. The effects of adrenaline may be potentiated by tricyclic antidepressants and mono amine oxidase inhibitors (MAO-inhibitors) and catechol-O-methyl transferase inhibitors (COMT inhibitors), thyroid hormones, theophylline, oxytocin, parasympatholytics, certain antihistamines (diphenhydramine, chlorpheniramine), levodopa and alcohol.
The vasoconstricting and hypertensive effects of adrenaline are antagonised by alpha-adrenergic blocking drugs, such as phentolamine. If prolonged hypotension follows such measures, it may be necessary to administer another pressor drug, such as levarterenol.
Adrenaline inhibits the secretion of insulin, thus increasing the blood glucose level. It may be necessary for diabetic patients receiving adrenaline to increase their dosage of insulin or oral hypoglycaemic drugs.
The cardiostimulating and bronchodilating effects of adrenaline are antagonised by beta-adrenergic blocking drugs, such as propranolol.
Adrenaline has been used for years in the treatment of allergic emergencies and its use is well documented in the literature. No clinical trials were performed in conjunction with this application.
Pregnancy:
Adrenaline should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
Breastfeeding:
Adrenaline is not orally bioavailable; any adrenaline excreted in breast milk would not be expected to have any effect on the nursing infant.
Fertility:
As adrenaline is a substance that naturally occurs in the body, it is unlikely that this drug would have any detrimental effects on fertility.
The patient's ability to drive and use machines may be affected by the anaphylactic reaction, as well as by possible adverse reactions to adrenaline.
Repeated dose toxicity studies were not performed in conjunction with this application. Side effects associated with adrenaline's alpha and beta receptor activity may include palpitations, tachycardia, and hypertension as well as undesirable effects on the central nervous system, sweating, nausea and vomiting, respiratory difficulty, pallor, dizziness, weakness, tremor, headache, apprehension, nervousness and anxiety. Cardiac arrhythmias may follow administration of adrenaline.
Evaluation of undesirable effects is based on the following frequency information:
-Very common (≥1/10)
-Common (≥1/100 to < 1/10)
-Uncommon (≥1/1 000 to < 1/100)
-Rare (≥1/10 000 to < 1/1 000)
-Very rare (< 1/10 000)
-Not known (Frequency cannot be estimated from the available data)
Organ System
Frequency
Adverse drug reaction
Infections and infestations
Frequency not known
Injection site infection *
Psychiatric disorders
Frequency not known
Anxiety
Nervous system disorders
Frequency not known
Headache, dizziness, tremor
Cardiac disorders
Rare
Stress cardiomyopathy
Frequency not known
Tachycardia, cardiac arrhythmia, palpitations, fatal ventricular fibrillation, angina
Vascular disorders
Frequency not known
Hypertension, pallor, peripheral ischaemia following accidental injection of the auto-injector in hands or feet
Respiratory, thoracic and mediastinal disorders
Frequency not Known
Respiratory difficulties
Gastrointestinal disorders
Frequency not known
Nausea, vomiting
Skin and subcutaneous tissue disorders
Frequency not known
Hyperhidrosis
General disorders and administration site condition
Frequency not known
Asthenia, accidental injections** can lead to injury at the injection site resulting in bruising, bleeding, discoloration, erythema or skeletal injury
* rare cases of serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene) are known from post-marketing experience
**Adverse reactions experienced as a result of accidental injections may include increased heart rate, local reactions including injection site pallor, coldness and hypoesthesia or injury at the injection site resulting in bruising, bleeding, discoloration, erythema or skeletal injury.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms:
Overdose or inadvertent intravascular or intra-osseus injection of adrenaline may cause cerebral haemorrhage resulting from a sharp rise in blood pressure. Fatalities may also result from pulmonary oedema because of peripheral vascular constriction together with cardiac stimulation.
Management:
Pressor effects of adrenaline may be counteracted by rapidly acting vasodilators or alpha-adrenergic blocking drugs. If prolonged hypotension follows such measures, it may be necessary to administer another pressor drug, such as levarterenol.
If an adrenaline overdose induces pulmonary oedema that interferes with respiration, treatment consists of a rapidly acting alpha-adrenergic blocking drug such as phentolamine and/or intermittent positive-pressure respiration.
Adrenaline overdose can also cause transient bradycardia followed by tachycardia, and these may be accompanied by potentially fatal cardiac arrhythmias. Treatment of arrhythmias may consist of administration of beta-adrenergic blocking drugs.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
⚠ Not the same combination. This medicine contains Adrenaline. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about EpiPen Adrenaline (Epinephrine) 0.3 mg Auto-Injector. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.